Memantine

ApprovedCompleted
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Alzheimer's Disease

Conditions

Alzheimer's Disease

Trial Timeline

Jul 1, 2008 → Oct 1, 2010

About Memantine

Memantine is a approved stage product being developed by Lundbeck for Alzheimer's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00800709. Target conditions include Alzheimer's Disease.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (5)

NCT IDPhaseStatus
NCT00800709ApprovedCompleted
NCT00703430Pre-clinicalUNKNOWN
NCT00401167ApprovedCompleted
NCT00196703ApprovedUNKNOWN
NCT00857233Phase 3Terminated

Competing Products

20 competing products in Alzheimer's Disease

See all competitors
ProductCompanyStageHype Score
LY450139 + PlaceboEli LillyPhase 3
77
Solanezumab + PlaceboEli LillyPhase 3
77
LY450139 dihydrate + placeboEli LillyPhase 2
52
GSK4527226AlectorPhase 2
44
GSK4527226AlectorPhase 2
44
AL002AlectorPhase 2
44
Solanezumab + PlaceboEli LillyPhase 3
77
simufilamCassava SciencesPhase 2
44
Remternetug + PlaceboEli LillyPhase 3
77
solanezumabEli LillyPhase 2
52
LY2886721 + PlaceboEli LillyPhase 1
33
Gantenerumab + Gantenerumab + Gantenerumab + PlaceboChugai PharmaceuticalPhase 1
33
Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved
85
FK962Astellas PharmaPhase 2
52
ASP0777 + PlaceboAstellas PharmaPhase 1
33
Elenbecestat + PlaceboEisaiPhase 3
77
DonepezilEisaiApproved
85
Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg)EisaiPhase 3
77
Donepezil hydrochlorideEisaiPhase 3
77
Donepezil HydrochlorideEisaiPre-clinical
23